[go: up one dir, main page]

IT1261165B - Agente attivo per ridurre il livello ematico di glucocorticoidi e prevenire disturbi cerebrali da stress e senilita'. - Google Patents

Agente attivo per ridurre il livello ematico di glucocorticoidi e prevenire disturbi cerebrali da stress e senilita'.

Info

Publication number
IT1261165B
IT1261165B ITRM930034A ITRM930034A IT1261165B IT 1261165 B IT1261165 B IT 1261165B IT RM930034 A ITRM930034 A IT RM930034A IT RM930034 A ITRM930034 A IT RM930034A IT 1261165 B IT1261165 B IT 1261165B
Authority
IT
Italy
Prior art keywords
stress
active agent
glucocorticoids
senility
reduce
Prior art date
Application number
ITRM930034A
Other languages
English (en)
Inventor
Vincenzo Politi
Mario Materazzi
Stazio Giovanni Di
Luca Giovanna De
Original Assignee
Polifarma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polifarma Spa filed Critical Polifarma Spa
Priority to ITRM930034A priority Critical patent/IT1261165B/it
Publication of ITRM930034A0 publication Critical patent/ITRM930034A0/it
Priority to ES93830530T priority patent/ES2093953T3/es
Priority to EP93830530A priority patent/EP0608671B1/en
Priority to AT93830530T priority patent/ATE142878T1/de
Priority to DE69304885T priority patent/DE69304885T2/de
Priority to US08/179,203 priority patent/US5447951A/en
Priority to JP6005893A priority patent/JP2562278B2/ja
Publication of ITRM930034A1 publication Critical patent/ITRM930034A1/it
Application granted granted Critical
Publication of IT1261165B publication Critical patent/IT1261165B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'acido 3-indolpiruvico è un agente attivo per prevenire danni cerebrali derivanti dallo stress e dall'invecchiamento indotti da un eccesso a livello ematico di glucocorticoidi secreti dalla ghiandola surrenale.
ITRM930034A 1993-01-25 1993-01-25 Agente attivo per ridurre il livello ematico di glucocorticoidi e prevenire disturbi cerebrali da stress e senilita'. IT1261165B (it)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ITRM930034A IT1261165B (it) 1993-01-25 1993-01-25 Agente attivo per ridurre il livello ematico di glucocorticoidi e prevenire disturbi cerebrali da stress e senilita'.
ES93830530T ES2093953T3 (es) 1993-01-25 1993-12-29 Empleo del acido 3-indolpiruvico para reducir el nivel de glucocorticoides en sangre y para prevenir transtornos cerebrales.
EP93830530A EP0608671B1 (en) 1993-01-25 1993-12-29 Use of 3-indolepyruvic acid to reduce the level of glucocorticoids in the blood and to prevent cerebral disturbances
AT93830530T ATE142878T1 (de) 1993-01-25 1993-12-29 Verwendung der 3-indolbrenztraubensäure zur erniedrigung der glucocorticoidblutspiegel und zur vorbeugung cerebraler störungen
DE69304885T DE69304885T2 (de) 1993-01-25 1993-12-29 Verwendung der 3-Indolbrenztraubensäure zur Erniedrigung der Glucocorticoidblutspiegel und zur Vorbeugung cerebraler Störungen
US08/179,203 US5447951A (en) 1993-01-25 1994-01-10 Method for reducing the level of glucocorticoids in the blood and preventing cerebral disturbances
JP6005893A JP2562278B2 (ja) 1993-01-25 1994-01-24 血液中グルココルチコイドレベルの降下剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM930034A IT1261165B (it) 1993-01-25 1993-01-25 Agente attivo per ridurre il livello ematico di glucocorticoidi e prevenire disturbi cerebrali da stress e senilita'.

Publications (3)

Publication Number Publication Date
ITRM930034A0 ITRM930034A0 (it) 1993-01-25
ITRM930034A1 ITRM930034A1 (it) 1994-07-25
IT1261165B true IT1261165B (it) 1996-05-09

Family

ID=11401415

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM930034A IT1261165B (it) 1993-01-25 1993-01-25 Agente attivo per ridurre il livello ematico di glucocorticoidi e prevenire disturbi cerebrali da stress e senilita'.

Country Status (7)

Country Link
US (1) US5447951A (it)
EP (1) EP0608671B1 (it)
JP (1) JP2562278B2 (it)
AT (1) ATE142878T1 (it)
DE (1) DE69304885T2 (it)
ES (1) ES2093953T3 (it)
IT (1) IT1261165B (it)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100895662B1 (ko) * 2001-03-23 2009-05-07 코어셉트 쎄라퓨틱스, 잉크. 글루코코르티코이드 수용체 특이적 길항제를 이용한스트레스 장애의 치료 방법
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
CN103860694A (zh) * 2014-02-14 2014-06-18 四川蜀源博业医药科技有限公司 一种鼻腔用离子敏感型原位凝胶剂及其制备方法和用途
JP7093961B2 (ja) * 2018-02-13 2022-07-01 国立大学法人金沢大学 ストレス低減薬剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1148618B (it) * 1982-10-11 1986-12-03 Polifarma Spa Procedimento enzimatico per la produzione di acido 3-indolpiruvico e utilizzazione farmaceutica di questo
IT1184282B (it) * 1985-06-28 1987-10-22 Polifarma Spa Procedimento per la produzione di alfa-chetoacidi indolici a partire da un rispettivo alfa-ammino-acido,particolarmente per produrre acido indolpiruvico
IT1206078B (it) * 1987-06-03 1989-04-14 Polifarma Spa Procedimento per la produzione di acido 3-indolpiruvico e suoi derivati loro uso farmaceutico
IT1224546B (it) * 1988-09-29 1990-10-04 Polifarma Spa Utilizzatore farmaceutica di acido 3 -indolpiruvico come agente inibitore di patologie degenerative
IT1232167B (it) * 1989-08-08 1992-01-25 Polifarma Spa Uso cosmetico di acido 3-indolpiruvico

Also Published As

Publication number Publication date
US5447951A (en) 1995-09-05
JP2562278B2 (ja) 1996-12-11
EP0608671A1 (en) 1994-08-03
ES2093953T3 (es) 1997-01-01
JPH06234634A (ja) 1994-08-23
ATE142878T1 (de) 1996-10-15
ITRM930034A1 (it) 1994-07-25
DE69304885D1 (de) 1996-10-24
DE69304885T2 (de) 1997-03-27
ITRM930034A0 (it) 1993-01-25
EP0608671B1 (en) 1996-09-18

Similar Documents

Publication Publication Date Title
ITMI920162A1 (it) Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
AU576586B2 (en) Fluorochemical allophonates and treatment of fibrous substrates therewith
TW282393B (it)
IT8847884A0 (it) Elettrodo enzimatico e modulo di elettrodo nonche' relativo metodo di impiego
MX9600487A (es) Composiciones topicamente administrables que contienen derivados de acido 3-benzoilfenilacetico para el tratamiento de trastornos inflamatorios oftalmicos.
ITPD940043A0 (it) "esteri attivi di polisaccaridi carbossilici"
EP0716609A4 (en) METHODS AND COMPOSITIONS FOR STIMULATING AND INHIBITING TGF--g(b) ACTIVITY
IT1200852B (it) Procedimento e dispositivo per l'alimentazione di elementida montare
IT1263013B (it) Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
DK0631772T3 (da) Retinoidholdig sammensætning
ES2135094T3 (es) Agentes cosmeticos que contienen alquilglucamidas de acidos grasos y compuestos de silicona.
IT1261165B (it) Agente attivo per ridurre il livello ematico di glucocorticoidi e prevenire disturbi cerebrali da stress e senilita'.
MY101804A (en) Menthol soap
NO20002649L (no) Anvendelse av en blanding av diol og en alfa-hydroksysyre for behandling av hyperkeratotiske hudsykdommer
BG102342A (en) Optical active derivative of phenylpyrimidine as an anlgesics
IT9022343A0 (it) Dicarbonati e uretani dell'acido 4,5-diidrossi- e 4,5,8-triidrossi- 9,10-diosso-2-antracencarbossilico ad azione terapeutica
BG102043A (en) Preparation of clavulanates
MX9803901A (es) Compuestos de di-terbutilfenol que contienen azufre utiles como agentes anti-inflamatorios.
ATE211920T1 (de) Verwendung von relaxin als schmerzstiller und - dämpfer für starken schmerz
HU9500857D0 (en) Use of hyaluronic acid and forms to prevent arterial restenosis
NO179245C (no) Arylalkylestere av 4,5-dihydroksy-9,10-dihydro-9,10-diokso-2-antracenkarboksylsyre med terapeutisk aktivitet
IT8422962A1 (it) Perfezionamento ad un apparecchio ortopedico per sostenere e mobilizzare gli arti di motolesi
IT8547601A0 (it) Insieme di pannelli e pezzo di connessione nonche' procedimento perassemblarli
IT1264446B1 (it) Acido 3 (n-(2-mercapto-propionil-ammino-acetil))-tetraidrotiazolil-4- carbossilico come agente antiinfiammatorio e immunostimolante
Koshida Frequency Prediction of Micro-Vibration Occurrence with Earthquakes

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970128